ARNI & SGLT2 Inhibitors in HF

Heart failure (HF) has remained one of the most lethal and resource-intensive cardiovascular syndromes worldwide, with five-year mortality rates historically rivaling those of many cancers. For decades, the pharmacological management of heart failure with reduced ejection fraction (HFrEF) relied on neurohormonal blockade—specifically ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs). While these agents meaningfully reduced mortality, residual risk remained unacceptably high, prompting the search for therapies that could offer incremental survival benefit by targeting novel pathways. Two drug classes that emerged from this search—angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose co-transporter 2 (SGLT2) inhibitors—fundamentally altered the treatment landscape and are now enshrined as pillars of guideline-directed medical therapy (GDMT).

The central question driving these advances was deceptively simple: can we move beyond pure RAAS blockade and find complementary neurohormonal and metabolic pathways whose modulation further improves outcomes? The ARNI class answered this by simultaneously enhancing the natriuretic peptide system while blocking the deleterious effects of angiotensin II, and the SGLT2 inhibitors answered it through mechanisms that remain an area of active investigation—ranging from osmotic diuresis and improved cardiac energetics to attenuation of inflammation and cardiac fibrosis. Together, these two classes represent the most significant therapeutic advances in HF pharmacology in the past two decades.

Understanding ARNI and SGLT2 inhibitor therapy in HF requires a firm grasp of several interconnected physiological and pharmacological principles. The failing heart triggers a cascade of neurohormonal activation—including the RAAS, sympathetic nervous system, and natriuretic peptide system—that is initially compensatory but ultimately maladaptive when sustained. Both drug classes act on distinct components of this neurohormonal milieu, and their mechanisms are largely complementary, which is why combining them within a four-pillar regimen yields additive benefits.

The diagram above highlights why an ARB rather than an ACE inhibitor was chosen for the ARNI combination. Neprilysin degrades bradykinin, and ACE does as well; blocking both enzymes simultaneously (as omapatrilat did) causes bradykinin to accumulate excessively, leading to life-threatening angioedema. Using an ARB instead of an ACE inhibitor avoids this safety hazard while still providing robust RAAS blockade at the receptor level. Notably, sacubitril/valsartan must not be co-administered with an ACE inhibitor, and a 36-hour washout period is required when switching from an ACEi to an ARNI to prevent overlapping bradykinin potentiation. On the right side of the diagram, notice that the SGLT2 inhibitor's benefits are truly pleiotropic—no single pathway fully accounts for the clinical benefit observed, and the relative contribution of each mechanism remains an active area of investigation.

Sacubitril/Valsartan (Entresto®) — Key PK/PD Parameters

Sacubitril/valsartan is formulated as the sodium salt complex of the sacubitril prodrug and valsartan in a 1:1 molar ratio. The approved dosage forms are expressed as sacubitril/valsartan mg (e.g., 24/26 mg, 49/51 mg, 97/103 mg). After oral ingestion, sacubitril undergoes esterase-mediated conversion to its active metabolite LBQ657, which achieves peak plasma concentration (T_max) at approximately 2 hours with an elimination half-life of roughly 11.5 hours. Valsartan reaches T_max at 1.5 hours with a half-life of approximately 9.9 hours. The different half-lives mean that with twice-daily dosing, both components achieve effective steady-state concentrations within 3 days. The drug is 94–97% protein-bound and is metabolized hepatically (CYP450 plays a minimal role), with elimination occurring renally (for LBQ657) and via biliary excretion (for valsartan).

SGLT2 Inhibitors — Key PK/PD Parameters

Both dapagliflozin (Farxiga®) and empagliflozin (Jardiance®) are orally bioavailable C-glucoside derivatives that competitively and reversibly inhibit SGLT2. Dapagliflozin has an oral bioavailability of approximately 78%, reaches T_max in 2 hours, and has a half-life of approximately 12.9 hours, supporting once-daily dosing. Empagliflozin has similar kinetics with a T_½ of approximately 12.4 hours. Both agents are primarily metabolized via UGT-mediated glucuronidation rather than CYP450 pathways, which minimizes drug-drug interactions—a clinically important advantage in the polypharmacy-heavy HF population. SGLT2 inhibitors induce a glycosuric effect of approximately 60–80 grams of glucose per day, but their cardiovascular benefits emerge within weeks and appear independent of HbA₁c reduction.

The clinical adoption of both ARNI and SGLT2 inhibitors in HF was driven by large, well-designed randomized controlled trials. Understanding the design, population, primary endpoints, and key results of these trials is essential for interpreting current guidelines and anticipating how future evidence might expand or refine indications.

Several observations merit emphasis. First, PARADIGM-HF compared sacubitril/valsartan against an active comparator (enalapril at 10 mg BID), meaning the ARNI's benefit represents true superiority over existing best-in-class RAAS blockade rather than superiority over placebo. Second, the SGLT2 inhibitor trials enrolled large proportions of non-diabetic patients and found consistent benefit regardless of baseline HbA₁c, definitively establishing these agents as HF drugs rather than merely diabetes drugs with cardiac side benefits. Third, the EMPEROR-Preserved and DELIVER trials extended the SGLT2i indication into HFpEF—a population for which, until these results, no pharmacotherapy had convincingly reduced the primary composite endpoint.

Consider a clinical scenario in which you must systematically apply pharmacological principles to initiate and titrate guideline-directed medical therapy for a patient newly diagnosed with HFrEF. This worked example integrates mechanism of action knowledge, dosing protocols, and monitoring parameters into a clinical reasoning framework.

A clinically useful exercise is to directly compare the ARNI and SGLT2 inhibitor classes across several dimensions—mechanism, titration burden, drug interactions, and adverse effects—to appreciate why they are complementary rather than interchangeable within the four-pillar framework.

The success of ARNI and SGLT2 inhibitors has catalyzed a broader rethinking of HF pathophysiology and treatment strategy. Several advanced concepts and emerging therapeutic frontiers directly build upon the pharmacological principles underlying these two classes.

The trajectory of SGLT2 inhibitor research is particularly notable for how it has expanded beyond its original indication. What began as an oral hypoglycemic agent for type 2 diabetes mellitus has now become a cornerstone of therapy for HFrEF, HFpEF, and CKD—three conditions that share overlapping pathophysiology involving hemodynamic stress, inflammation, fibrosis, and metabolic derangement. Future investigations will likely explore SGLT2i in additional phenotypes such as atrial fibrillation, obesity-related cardiomyopathy, and post-cardiac surgery recovery. Similarly, the concept of augmenting endogenous cardioprotective peptide systems—pioneered by ARNI—may inspire next-generation therapies that modulate other vasoactive peptides such as apelin, relaxin, or adrenomedullin.